Menopause / HRT · Evidence-Based

The evidence moved on from 2002. Most marketing hasn't caught up.

CitedRx rates 9 menopause hormone therapy (HRT) telehealth providers out of 10. The 2002 Women's Health Initiative scare still shapes public fear of HRT today, despite substantial reinterpretation since: including a February 2026 FDA label change. We weight menopause-specific clinical specialization heavily, since the timing and dosing nuance in this category is real.

Last reviewed: September 2026 · 9 providers compared · See the clinical evidence →

How the CitedRx Score works: we score every provider out of 10 on whether prescribing follows current NAMS/ACOG guidance rather than either the outdated 2002 panic or an unqualified "it's totally safe now" overcorrection (see our WHI evidence deep-dive), plus independent rating, insurance/pricing support, degree of menopause-specific specialization, and regulatory standing. Specialization is weighted meaningfully here: a provider that treats menopause as its core focus, not one service among many, tends to handle the timing/dosing nuance better.

4 pts

Evidence Match

2 pts

Independent Rating

2 pts

Insurance & Support

1 pt

Specialization

1 pt

Regulatory Standing

The top 3, in depth

Elektra Health 8.5/10

Best for: evidence-first prescribing, no compounded pellets

Menopause-specialty telehealth (MDs, OB-GYNs, NPs, CNMs) that explicitly avoids compounded bioidentical formulations, pairing FDA-approved HRT with 1:1 coaching. Insurance coverage expanding to nearly 40 payer partners.

$249Initial consult (cash-pay)

FDA-Approved-FirstPrescribing approach

ExpandingInsurance coverage

Explicitly evidence-first prescribing means the WHI reanalysis and NAMS guidance in our research library applies most directly to what's prescribed.

Visit Elektra Health

Gennev 8.5/10

Best for: exclusively board-certified OB-GYN network + broad insurance

Network is exclusively board-certified OB-GYNs, many Menopause Society Certified Practitioners, prescribing aligned with current guidelines. Accepts Aetna, Anthem, and UnitedHealthcare.

$199Initial visit (self-pay)

FDA-Approved-FirstPrescribing approach

YesMajor insurance accepted

Exclusively OB-GYN network with broad insurance acceptance is a strong specialization + access combination.

Visit Gennev

Alloy Women's Health 7.2/10

Best for: low-cost entry with strong menopause specialization

Menopause-specialty telehealth that says it follows ACOG/NAMS guidelines and prescribes FDA-approved medications first, using compounded options (including testosterone) only when needed.

$49One-time consult

MixedPrescribing approach

4.3/5Trustpilot (2,100+ reviews)

Mostly FDA-approved-first with a compounded testosterone option available: ask which formulation you'd actually be prescribed.

Visit Alloy

9 providers compared

#	Provider	CitedRx Score	Prescribing approach	Best for	From
1	Elektra Health	8.5/10	FDA-Approved-First	Evidence-first, no compounded pellets	$249
2	Gennev	8.5/10	FDA-Approved-First	OB-GYN network + broad insurance	$199
3	Alloy Women's Health	7.2/10	Mixed	Low-cost entry, strong specialization	$49
4	Winona	6.8/10	Mixed	Highest-rated (4.6/5, 6,200+ reviews)	$89/mo
5	Midi Health	6.6/10	Mixed	Menopause-only specialty, PPO insurance	$150/visit
6	Evernow	6.3/10	FDA-Approved-First	Hormonal + non-hormonal options	From $35/mo
7	Rory	6.0/10	Mixed	Part of a broader multi-condition platform	Varies
8	Hers	5.5/10	Mixed	New menopause line, large parent platform	$134/mo
9	Maven Clinic	5.5/10	Mixed	Broad women's-health platform (mostly employer-sponsored)	Varies

Evernow's low rating (2.0/5, small sample) reflects reviewer complaints about provider credentialing and lab access: worth verifying directly. Maven is primarily employer-sponsored, which limits direct individual access compared to the rest of this list. See our research library for full evidence and citations.

How we scored these

Evidence Match (4 pts). Full credit for prescribing that follows current NAMS/ACOG guidance and defaults to FDA-approved formulations; partial credit where compounded (non-FDA-approved) hormone products are part of the standard offering.
Independent Rating (2 pts). Scaled from the best available third-party rating; several providers in this category have thin or no independent rating data, which we note rather than estimate.
Insurance & Support (2 pts). Full credit for broad major-insurance acceptance; partial for FSA/HSA-only or limited payer networks.
Specialization (1 pt). Full credit for menopause-dedicated clinicians and infrastructure; partial for general telehealth platforms offering HRT as one of many services.
Regulatory Standing (1 pt). Full credit by default; deducted for documented, provider-specific quality complaints (not unrelated parent-company issues).

Scores are CitedRx's own composite, not a clinical endorsement. Score order reflects the factors above, not payment from a provider. CitedRx may earn a referral fee if you sign up through a link on this page: see the disclosure in the footer.

Read the full WHI evidence deep-dive →

Frequently asked questions

Is HRT safe for menopause symptoms?

It depends heavily on your age and how long ago you went through menopause: this is not a single yes/no answer. Current consensus (NAMS's 2022 position statement, and a February 2026 FDA label change) is that benefits outweigh risks for most healthy, symptomatic women under 60 or within 10 years of menopause onset. The risk profile is less favorable for women starting HRT later.

What did the Women's Health Initiative (WHI) study actually find?

The 2002 WHI trial found combined estrogen+progestin therapy increased breast cancer, heart disease, and stroke risk in postmenopausal women averaging 63 years old: older than typical HRT candidates today. Later reanalysis by age found the risk profile was substantially more favorable for women starting HRT within 10 years of menopause onset. The estrogen-only arm (for women without a uterus) did not show increased breast cancer risk.

Is transdermal (patch or gel) estrogen safer than oral pills?

For blood clot risk specifically, yes: meta-analyses show oral estrogen carries a meaningfully elevated venous thromboembolism risk (RR ~1.9) while transdermal estrogen shows essentially no elevated risk (RR ~1.0), likely because transdermal delivery bypasses first-pass liver metabolism.

Did the FDA remove the black-box warning from HRT?

In February 2026, the FDA approved label changes removing boxed-warning language on cardiovascular disease, breast cancer, and dementia from several menopausal hormone therapy products. Medical societies supported this specifically for low-dose vaginal estrogen but cautioned that systemic HRT still carries individualized risks warranting real counseling.

Does specialization matter when choosing an HRT provider?

Yes. Menopause care involves genuine nuance around timing, dosing, and route of administration. A provider specializing specifically in menopause care, with clinicians trained in current NAMS/ACOG guidance, is a legitimate quality signal over a general telehealth platform offering HRT as one of many services.

Sources

CitedRx is an independent information resource and is not affiliated with the telehealth providers listed above. Pricing, ratings, and regulatory status are sourced from provider sites and public reviews; figures can change and should be confirmed with the provider directly. This page is for informational purposes only and is not medical advice: talk to a licensed clinician about whether HRT is appropriate for you, given your individual age, timing, and risk factors. CitedRx may earn a referral fee if you sign up with a provider through a link on this page; this does not affect score or ranking order.